Olaparib

Ovarian cancer

Chemotherapy

Maintenance therapy

BRCA mutation

Polymerase

Biology

Gene

Poly ADP ribose polymerase

Cancer

Internal medicine

Oncology

Bevacizumab

Genetics

Medicine

New England Journal of Medicine

Olaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of combining maintenance olaparib and bevacizumab in patients regardless of BRCA mutation status is unknown.

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer